High Linc01116 Expression May Contribute to a Poor Prognosis in Various Cancers Based on Systematic Reviews and Meta-analyses

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2024 Dec 22

PMID 39710641

Authors

Si-Tong Fan

Dan Li

Qun-Xian Zhang

Li-Qiang Xu

Tao Zeng

Qiang Liu

Qiang Guo

Chen-Yi Lin

Wei-Min Luo

Affiliations

Soon will be listed here.

Abstract

Background: Long non-coding RNA 01116 (linc01116) has been shown to be dysregulated in many tumors, and is closely related to the prognosis. This meta-analysis aimed to examine the correlation between linc01116 expression and cancer prognosis.

Methods: Six electronic databases were searched, and eligible studies were screened based on the inclusion and exclusion criteria. Data including hazard ratios (HRs) and 95% confidence intervals (CIs), TNM stage, distant metastasis (DM) status, lymph node metastasis (LNM) status, and tumor size were extracted from the included studies. HRs and odds ratios (ORs) with their corresponding 95% CIs were separately pooled to assess the relationship between linc01116 expression and cancer prognosis. Sensitivity analysis and Begg's test were performed to assess publication or other biases.

Results: A total of 12 studies involving 809 patients were included in this meta-analysis. Analysis of pooled HRs with 95% CIs showed that high linc01116 expression was significantly correlated with poor overall survival (OS) (HR = 2.096; 95% CI: 1.555-2.638), progression-free survival (PFS) (HR, 1.9314; 95% CI: 1.020-3.657), disease-free survival (DFS) (HR = 2.067; 95% CI: 1.0889-3.9238), an advanced TNM stage (OR, 1.803; 95% CI: 1.270-2.562), and a poor histological grade (OR, 1.968; 95% CI: 1.288-3.007). However, no significant correlation was observed between linc01116 expression and LNM (OR, 1.198; 95% CI: 0.831-1.728), DM (OR, 1.114; 95% CI: 0.757-1.638), tumor size (OR, 1.336; 95% CI: 0.989-1.804), depth of invasion (OR, 1.375; 95% CI: 0.756-2.501), age (OR, 0.976; 95% CI: 0.742-1.283), or sex (OR, 0.810; 95% CI: 0.599-1.094). Sensitivity analysis indicated that the overall results of OS analysis were reliable and robust. In addition, Begg's test showed that none of the included studies had significant publication bias.

Conclusion: linc01116 is upregulated in most cancers, and this upregulation is associated with a poor prognosis. Therefore, linc01116 serves as a promising therapeutic target and prognostic biomarker for cancer.

References

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

Zhang Y, Tao Y, Liao Q . Long noncoding RNA: a crosslink in biological regulatory network. Brief Bioinform. 2017; 19(5):930-945. DOI: 10.1093/bib/bbx042. View

Xu C, Ping Y, Zhao H, Ning S, Xia P, Wang W . LncNetP, a systematical lncRNA prioritization approach based on ceRNA and disease phenotype association assumptions. Oncotarget. 2018; 8(70):114603-114612. PMC: 5777717. DOI: 10.18632/oncotarget.23059. View

Liang W, Wu J, Qiu X . LINC01116 facilitates colorectal cancer cell proliferation and angiogenesis through targeting EZH2-regulated TPM1. J Transl Med. 2021; 19(1):45. PMC: 7836198. DOI: 10.1186/s12967-021-02707-7. View

Karimi Taheri M, Ghanbari S, Gholipour A, Givi T, Sadeghizadeh M . LINC01116 affects patient survival differently and is dissimilarly expressed in ER+ and ER- breast cancer samples. Cancer Rep (Hoboken). 2023; 6(8):e1848. PMC: 10432450. DOI: 10.1002/cnr2.1848. View

Herman A, Tsitsipatis D, Gorospe M . Integrated lncRNA function upon genomic and epigenomic regulation. Mol Cell. 2022; 82(12):2252-2266. PMC: 9219586. DOI: 10.1016/j.molcel.2022.05.027. View

Haghighi R, Castillo-Acobo R, Amin A, Ehymayed H, Alhili F, Mirzaei M . A thorough understanding of the role of lncRNA in prostate cancer pathogenesis; Current knowledge and future research directions. Pathol Res Pract. 2023; 248:154666. DOI: 10.1016/j.prp.2023.154666. View

Ma Y, Zhang J, Wen L, Lin A . Membrane-lipid associated lncRNA: A new regulator in cancer signaling. Cancer Lett. 2018; 419:27-29. DOI: 10.1016/j.canlet.2018.01.008. View

Wang H, Lu B, Ren S, Wu F, Wang X, Yan C . Long Noncoding RNA LINC01116 Contributes to Gefitinib Resistance in Non-small Cell Lung Cancer through Regulating IFI44. Mol Ther Nucleic Acids. 2019; 19:218-227. PMC: 6920314. DOI: 10.1016/j.omtn.2019.10.039. View

10.

Liao X, Zhan W, Zhang J, Cheng Z, Li L, Tian T . Long noncoding RNA LINC01234 promoted cell proliferation and invasion via miR-1284/TRAF6 axis in colorectal cancer. J Cell Biochem. 2020; 121(10):4295-4309. DOI: 10.1002/jcb.29618. View

11.

Duffy M, Synnott N, Crown J . Mutant p53 as a target for cancer treatment. Eur J Cancer. 2017; 83:258-265. DOI: 10.1016/j.ejca.2017.06.023. View

12.

Ferre F, Colantoni A, Helmer-Citterich M . Revealing protein-lncRNA interaction. Brief Bioinform. 2015; 17(1):106-16. PMC: 4719072. DOI: 10.1093/bib/bbv031. View

13.

Beaver L, Kuintzle R, Buchanan A, Wiley M, Glasser S, Wong C . Long noncoding RNAs and sulforaphane: a target for chemoprevention and suppression of prostate cancer. J Nutr Biochem. 2017; 42:72-83. PMC: 5360475. DOI: 10.1016/j.jnutbio.2017.01.001. View

14.

Fang X, Ren L, Shrestha S, Ji Q, Xu Z, Wang D . LINC01116 modulates EMT process via binding with AGO1 mRNA in oesophageal squamous cell carcinoma. Biochim Biophys Acta Mol Cell Res. 2023; 1870(5):119447. DOI: 10.1016/j.bbamcr.2023.119447. View

15.

Huang Z, Zhou J, Peng Y, He W, Huang C . The role of long noncoding RNAs in hepatocellular carcinoma. Mol Cancer. 2020; 19(1):77. PMC: 7161154. DOI: 10.1186/s12943-020-01188-4. View

16.

Shang B, Li Z, Li M, Jiang S, Feng Z, Cao Z . Silencing LINC01116 suppresses the development of lung adenocarcinoma via the AKT signaling pathway. Thorac Cancer. 2021; 12(14):2093-2103. PMC: 8287011. DOI: 10.1111/1759-7714.14042. View

17.

Chiorean E, Coveler A . Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther. 2015; 9:3529-45. PMC: 4500614. DOI: 10.2147/DDDT.S60328. View

18.

Li T, Zhou S, Yang Y, Xu Y, Gong X, Cheng Y . LncRNA MNX1-AS1: A novel oncogenic propellant in cancers. Biomed Pharmacother. 2022; 149:112801. DOI: 10.1016/j.biopha.2022.112801. View

19.

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

20.

Entezari M, Ghanbarirad M, Taheriazam A, Sadrkhanloo M, Zabolian A, Goharrizi M . Long non-coding RNAs and exosomal lncRNAs: Potential functions in lung cancer progression, drug resistance and tumor microenvironment remodeling. Biomed Pharmacother. 2022; 150:112963. DOI: 10.1016/j.biopha.2022.112963. View